Eric Simpson, MD
Enriched profileProfessor of Dermatology (Frances J. Storrs, M.D. Medical Dermatology Professor); Director, Frances J. Storrs and Jon M. Hanifin CLEAR Eczema Center · Oregon Health & Science University
Eric Simpson is Professor of Dermatology (Frances J. Storrs, M.D. Medical Dermatology Professor); Director, Frances J. Storrs and Jon M. Hanifin CLEAR Eczema Center at Oregon Health & Science University. OpenAlex indexes 553 publications with 23,478 citations (h-index 75); ClinicalTrials.gov lists 12 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Dermatology profiles in the findmyKOL directory. Clarivate lists Eric Simpson as a Highly Cited Researcher (Clinical Medicine, 2021-2024; Cross-Field, 2020).
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Eric Simpson, MD, is Professor of Dermatology (Frances J. Storrs, M.D. Medical Dermatology Professor) at Oregon Health & Science University, School of Medicine, Department of Dermatology, Portland, OR. The public record shows 553 publications with 23,478 citations (h-index 75), centered on Dermatology and Skin Diseases, Allergic Rhinitis and Sensitization, Asthma and respiratory diseases. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 28 companies, 4 NIH-funded awards (2010–2025).
- Most recent indexed publication: 2026 · The Journal of dermatological treatment
- Top research focus: Dermatology and Skin Diseases
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 28 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 47 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 208.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- A Community-based Assessment of Skin Care, Allergies, and Eczema
Sponsor: Oregon Health and Science University
Industry payments
Updated 14 Oct 2026
28 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year202516 payments$121,152openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year202512 payments$33,407openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year202522 payments$10,521openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
56.6%Interleukin-4 Receptor alpha Antagonist37.6%Dupixent Pen65%Dupixent Syringe35%Part D<11 patientsCorticosteroid19%Triamcinolone Acetonide100%Part D≥35 patientsCancer & immunology
22.1%Calcineurin inhibitor14.3%Tacrolimus100%Part D≥19 patientsFolate Analog Metabolic Inhibitor7.8%Methotrexate100%Part D<11 patientsSensory organs
21.3%Corticosteroid21.3%Clobetasol Propionate76%Hydrocortisone24%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
4 NIH research awards on record, funded 2010–2025 per NIH RePORTER. The latest:
- Parent-directed remote identification and severity assessments enabling decentralized trials in atopic dermatitis
Oregon Health & Science University
FY2025$302,888R01AR082107 - Parent-directed remote identification and severity assessments enabling decentralized trials in atopic dermatitis
Oregon Health & Science University
FY2024$402,616R01AR082107 - A Community-based Assessment of Skin Care, Allergies, and Eczema: The CASCADE Trial
Oregon Health & Science University
FY2023$300,000R01AR071057
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary.
The Journal of dermatological treatment
Article2026 - Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.
The Journal of dermatological treatment
Clinical Trial2026 - Severity bands for atopic dermatitis measures: Analysis from adult dupilumab randomized clinical trials.
Journal of the European Academy of Dermatology and Venereology
Article2026 - Defining the Potential for Disease Modification in Atopic Dermatitis.
American journal of clinical dermatology
Article2026
Most-cited works
by citation count (OpenAlex)- 01Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisArticle2,056 citations2016
- 02Eczema Prevalence in the United States: Data from the 2003 National Survey of Children's HealthArticle725 citations2010
- 03
- 04
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/eric-simpson-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Eric-Simpson-2
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
nationaleczema.org/blog/podcast-itchy-bumps
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nationaleczema.org ↗ - Spotify
open.spotify.com/episode/5zVcTqJ8T4chCU7yUW4sGt
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →open.spotify.com ↗ - Other
pedraresearch.org/2020/06/17/podcast-a-roadmap-for-navigating-the-new-eczema-treatment-landscape-with-dr-eric-simpson
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pedraresearch.org ↗ - Other
hcplive.com/view/eric-simpson-md-new-findings-tapinarof-cream-adults-children-atopic-dermatitis
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcplive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
- Board Certified
American Board of Dermatology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
Editorial & leadership roles
journal and society appointments- Research Advisory Committee (RAC) Chair
National Eczema Association Scientific & Medical Advisory Council
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nationaleczema.org ↗ - Member: American Academy of Dermatology
American Contact Dermatitis Society, American Dermatological Association, Dermatology Foundation Leaders Society, International Society of Atopic Dermatitis …
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗ - Chair
Steering Committee for Phase 2b/Phase 3 dupilumab (IL-4/IL-13 antibody) trials in atopic dermatitis; lead international investigator on multiple AD therapeutic trials leading to FDA approvals
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →media.mycme.com ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine2021202220232024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
- Cross-Field2020verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
Secondary affiliations
appointments beyond the home institution- Scientific Advisor
ASLAN Pharmaceuticals
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →theorg.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pedraresearch.org ↗
- Podcast guest
"The Impact of Sharing Your Eczema Story" - Eczema Out Loud (National Eczema Association podcast series)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →open.spotify.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hcplive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ohsu.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Maziarz, MD
Oregon Health & Science University
Wayne Clark, MD
Oregon Health & Science University
Helmi Lutsep, MD
Oregon Health & Science University
Eric Suhler, MD
Oregon Health & Science University
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania